BeiGene Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • BeiGene's estimated annual revenue is currently $1.1B per year.(i)
  • BeiGene received $800.0M in venture funding in January 2018.
  • BeiGene's estimated revenue per employee is $347,883
  • BeiGene's total funding is $6.8B.
  • BeiGene's current valuation is $25.4B. (January 2022)

Employee Data

  • BeiGene has 3047 Employees.(i)
  • BeiGene grew their employee count by 15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

BeiGene, Ltd. (NASDAQ: BGNE) is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,300 employees in China, the United States (Cambridge, MA; Fort Lee, NJ; Emeryville, CA & San Mateo, CA), Switzerland and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for the treatment of cancer. BeiGene is working to create combination solutions aimed at having both a meaningful and lasting impact on cancer patients. For more information, see



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





BeiGene News

2022-04-20 - BeiGene Introduces Global Environmental, Social, and Governance ...

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment...

2022-04-20 - BeiGene, Zai Lab Look To Clear US Delisting Uncertainties

Both trade on the Hong Kong Stock Exchange and BeiGene is also listed on Shanghai's STAR market, becoming the first biotech from China to be...

2022-04-13 - BeiGene nabs another PD-1 approval in China. Can partner ...

On Friday, BeiGene scored an approval in China for tislelizumab as a treatment for second-line patients with locally advanced or metastatic esophageal...

2021-06-17 - BEIGENE, LTD. BeiGene : Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the first patient was dosed in the global Phase 3 AdvanTIG-302 trial of BeiGene’s investigational anti-TIGIT antibody ociperlim ...

2021-03-02 - Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Mar 2, 2021-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA ® (zanubrutinib) has been approved by Health Can ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

BeiGene Funding

DateAmountRoundLead InvestorsReference